Lybecker, Kristina M. - In: Managerial and Decision Economics 28 (2007) 4-5, pp. 509-520
The debate over access to medicines has principally centered on pharmaceutical patents and prohibitively high drug prices. Although a less recognized problem, counterfeit pharmaceuticals are certainly a more insidious barrier to access. Pharmaceutical counterfeiting is an invisible threat, not...